Oncology Drug Reference Sheet: Capecitabine
Wendy Pritchett, MSN, RN, OCN®, and Karen Kinsley, BSN, RN, OCN®
Voice
Description
Capecitabine (Xeloda®) was approved by the U.S. Food and Drug Administration (FDA) in 1998 as a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education